Search

Brian A. Whiteman

Examiner (ID: 15660, Phone: (571)272-0764 , Office: P/1674 )

Most Active Art Unit
1635
Art Unit(s)
1674, 1636, 1633, 1635
Total Applications
1778
Issued Applications
936
Pending Applications
245
Abandoned Applications
622

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 15960471 [patent_doc_number] => 20200163987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING A BLEEDING EVENT IN A SUBJECT HAVING HEMOPHILIA [patent_app_type] => utility [patent_app_number] => 16/630044 [patent_app_country] => US [patent_app_date] => 2018-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54789 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16630044 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/630044
METHODS AND COMPOSITIONS FOR TREATING A BLEEDING EVENT IN A SUBJECT HAVING HEMOPHILIA Jul 9, 2018 Abandoned
Array ( [id] => 18413379 [patent_doc_number] => 11667914 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-06 [patent_title] => Chemically ligated RNAs for CRISPR/Cas9-1gRNA complexes as antiviral therapeutic agents [patent_app_type] => utility [patent_app_number] => 16/029653 [patent_app_country] => US [patent_app_date] => 2018-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 7363 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16029653 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/029653
Chemically ligated RNAs for CRISPR/Cas9-1gRNA complexes as antiviral therapeutic agents Jul 8, 2018 Issued
Array ( [id] => 18413379 [patent_doc_number] => 11667914 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-06 [patent_title] => Chemically ligated RNAs for CRISPR/Cas9-1gRNA complexes as antiviral therapeutic agents [patent_app_type] => utility [patent_app_number] => 16/029653 [patent_app_country] => US [patent_app_date] => 2018-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 7363 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16029653 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/029653
Chemically ligated RNAs for CRISPR/Cas9-1gRNA complexes as antiviral therapeutic agents Jul 8, 2018 Issued
Array ( [id] => 16999739 [patent_doc_number] => 11078535 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => Presymptomatic micro RNA targets for treatment of neurodegeneration pathology [patent_app_type] => utility [patent_app_number] => 16/631866 [patent_app_country] => US [patent_app_date] => 2018-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 7 [patent_no_of_words] => 14867 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16631866 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/631866
Presymptomatic micro RNA targets for treatment of neurodegeneration pathology Jul 6, 2018 Issued
Array ( [id] => 15634875 [patent_doc_number] => 10590416 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-17 [patent_title] => RNAi agents for inhibiting expression of alpha-ENaC and methods of use [patent_app_type] => utility [patent_app_number] => 16/028006 [patent_app_country] => US [patent_app_date] => 2018-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 36 [patent_no_of_words] => 33218 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16028006 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/028006
RNAi agents for inhibiting expression of alpha-ENaC and methods of use Jul 4, 2018 Issued
Array ( [id] => 16855209 [patent_doc_number] => 20210155954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => CRISPR LOGIC CIRCUITS FOR SAFER AND CONTROLLABLE GENE THERAPIES [patent_app_type] => utility [patent_app_number] => 16/626021 [patent_app_country] => US [patent_app_date] => 2018-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9627 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16626021 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/626021
CRISPR logic circuits for safer and controllable gene therapies Jun 25, 2018 Issued
Array ( [id] => 17043796 [patent_doc_number] => 11096956 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-24 [patent_title] => Antisense oligomers and uses thereof [patent_app_type] => utility [patent_app_number] => 16/007435 [patent_app_country] => US [patent_app_date] => 2018-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 172 [patent_figures_cnt] => 206 [patent_no_of_words] => 282950 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 169 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16007435 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/007435
Antisense oligomers and uses thereof Jun 12, 2018 Issued
Array ( [id] => 13444869 [patent_doc_number] => 20180273977 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => MULTIMERIC MRNA [patent_app_type] => utility [patent_app_number] => 16/001751 [patent_app_country] => US [patent_app_date] => 2018-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16001751 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/001751
MULTIMERIC MRNA Jun 5, 2018 Abandoned
Array ( [id] => 13982661 [patent_doc_number] => 20190060488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (siNA) CONJUGATED TO A LIPOPHILIC MOIETY [patent_app_type] => utility [patent_app_number] => 15/994450 [patent_app_country] => US [patent_app_date] => 2018-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15994450 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/994450
Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety May 30, 2018 Issued
Array ( [id] => 16799109 [patent_doc_number] => 10994025 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-04 [patent_title] => Argonaute protein-double stranded RNA complexes and uses related thereto [patent_app_type] => utility [patent_app_number] => 15/977778 [patent_app_country] => US [patent_app_date] => 2018-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 62 [patent_no_of_words] => 22147 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15977778 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/977778
Argonaute protein-double stranded RNA complexes and uses related thereto May 10, 2018 Issued
Array ( [id] => 16013553 [patent_doc_number] => 20200181619 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => APTAZYME-EMBEDDED GUIDE RNAS FOR USE WITH CRISPR-CAS9 IN GENOME EDITING AND TRANSCRIPTIONAL ACTIVATION [patent_app_type] => utility [patent_app_number] => 16/612988 [patent_app_country] => US [patent_app_date] => 2018-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26240 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -120 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16612988 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/612988
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation May 10, 2018 Issued
Array ( [id] => 19060423 [patent_doc_number] => 11939633 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => COTL1 protein involved in maintaining homeostasis of hematopoietic stem cell, and use thereof [patent_app_type] => utility [patent_app_number] => 16/612031 [patent_app_country] => US [patent_app_date] => 2018-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 7486 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16612031 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/612031
COTL1 protein involved in maintaining homeostasis of hematopoietic stem cell, and use thereof May 9, 2018 Issued
Array ( [id] => 15557455 [patent_doc_number] => 20200063139 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => PREVENTION AND/OR TREATMENT OF INFLAMMATORY SKIN DISEASE [patent_app_type] => utility [patent_app_number] => 16/611847 [patent_app_country] => US [patent_app_date] => 2018-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8605 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16611847 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/611847
Prevention and/or treatment of inflammatory skin disease May 2, 2018 Issued
Array ( [id] => 16028671 [patent_doc_number] => 10676744 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-09 [patent_title] => Modulation of adipose tissue macrophage phenotype by use of MicroRNA-30 [patent_app_type] => utility [patent_app_number] => 15/966171 [patent_app_country] => US [patent_app_date] => 2018-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 29 [patent_no_of_words] => 6164 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15966171 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/966171
Modulation of adipose tissue macrophage phenotype by use of MicroRNA-30 Apr 29, 2018 Issued
Array ( [id] => 16506476 [patent_doc_number] => 20200385732 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => BIOMARKER FOR SMALL CELL LUNG CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 16/606969 [patent_app_country] => US [patent_app_date] => 2018-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10365 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16606969 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/606969
BIOMARKER FOR SMALL CELL LUNG CANCER THERAPY Apr 22, 2018 Abandoned
Array ( [id] => 19969847 [patent_doc_number] => 12338440 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-24 [patent_title] => Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof [patent_app_type] => utility [patent_app_number] => 16/316298 [patent_app_country] => US [patent_app_date] => 2018-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 18 [patent_no_of_words] => 54069 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16316298 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/316298
Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof Apr 19, 2018 Issued
Array ( [id] => 16650208 [patent_doc_number] => 10927373 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Compositions and methods for inhibiting gene expression of Hif2alpha [patent_app_type] => utility [patent_app_number] => 15/954316 [patent_app_country] => US [patent_app_date] => 2018-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 26672 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15954316 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/954316
Compositions and methods for inhibiting gene expression of Hif2alpha Apr 15, 2018 Issued
Array ( [id] => 17800382 [patent_doc_number] => 11414667 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-16 [patent_title] => High efficiency aptamer complex comprising branched DNA and aptamer, and use thereof [patent_app_type] => utility [patent_app_number] => 16/963315 [patent_app_country] => US [patent_app_date] => 2018-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 18 [patent_no_of_words] => 7411 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16963315 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/963315
High efficiency aptamer complex comprising branched DNA and aptamer, and use thereof Apr 12, 2018 Issued
Array ( [id] => 13622871 [patent_doc_number] => 20180362987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => TARGETED AUGMENTATION OF NUCLEAR GENE OUTPUT [patent_app_type] => utility [patent_app_number] => 15/949902 [patent_app_country] => US [patent_app_date] => 2018-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34075 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15949902 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/949902
Targeted augmentation of nuclear gene output Apr 9, 2018 Issued
Array ( [id] => 13622853 [patent_doc_number] => 20180362978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes [patent_app_type] => utility [patent_app_number] => 15/948624 [patent_app_country] => US [patent_app_date] => 2018-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32024 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15948624 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/948624
Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes Apr 8, 2018 Abandoned
Menu